glp 1 dual agonist GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes Dose-equivalence reference based on pivotal

2021 Apr 19

Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma

Bartels GL, Remme WJ, Holwerda KJ, Kruijssen DA

Although the primary endpoint was not achieved, secondary endpoints and exploratory analyses suggest that participants with TNFi-IR PsA, particularly those with elevated CRP, could derive clinically meaningful benefits with guselkumab and golimumab combination therapy, with no new safety concerns, warranting further investigation, the researchers wrote

doi: 10.1111/and.13644 14 SongFLokeYKWalshTGlennyAMEastwoodAJAltmanDG

As research moves forward, Ipamorelin and Tesamorelin may be further improved to create more focused fat-loss solutions, offering new therapies for dealing with obesity and metabolic disorders